Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation

7-Year observational results

Bernhard K. Krämer, Giuseppe Montagnino, Bernd Krüger, Raimund Margreiter, Christoph J. Olbricht, Roberto Marcen, Urban Sester, Ulrich Kunzendorf, Karl Heinz Dietl, Paolo Rigotti, Claudio Ronco, Silke Hörsch, Bernhard Banas, Ferdinand Mühlbacher, Manuel Arias

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1% in the tacrolimus arm and 59.9% in the CsA-ME arm, graft survival rates amounted to 82.6% and 80.6%, and patient survival rates to 89.9% and 88.1%. Estimated combined endpoint-free survival rates were 60.2% in the tacrolimus arm and 47.0% in the CsA-ME arm (P =

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalTransplant International
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Tacrolimus
Kidney Transplantation
Cyclosporine
Safety
Arm
Survival Rate
Graft Survival
Research Personnel
Transplants
Population

Keywords

  • acute rejection
  • adverse events
  • calcineurin inhibitor
  • investigator-initiated study
  • long-term follow-up

ASJC Scopus subject areas

  • Transplantation

Cite this

Krämer, B. K., Montagnino, G., Krüger, B., Margreiter, R., Olbricht, C. J., Marcen, R., ... Arias, M. (2016). Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-Year observational results. Transplant International, 29(3), 307-314. https://doi.org/10.1111/tri.12716

Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation : 7-Year observational results. / Krämer, Bernhard K.; Montagnino, Giuseppe; Krüger, Bernd; Margreiter, Raimund; Olbricht, Christoph J.; Marcen, Roberto; Sester, Urban; Kunzendorf, Ulrich; Dietl, Karl Heinz; Rigotti, Paolo; Ronco, Claudio; Hörsch, Silke; Banas, Bernhard; Mühlbacher, Ferdinand; Arias, Manuel.

In: Transplant International, Vol. 29, No. 3, 01.03.2016, p. 307-314.

Research output: Contribution to journalArticle

Krämer, BK, Montagnino, G, Krüger, B, Margreiter, R, Olbricht, CJ, Marcen, R, Sester, U, Kunzendorf, U, Dietl, KH, Rigotti, P, Ronco, C, Hörsch, S, Banas, B, Mühlbacher, F & Arias, M 2016, 'Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-Year observational results', Transplant International, vol. 29, no. 3, pp. 307-314. https://doi.org/10.1111/tri.12716
Krämer, Bernhard K. ; Montagnino, Giuseppe ; Krüger, Bernd ; Margreiter, Raimund ; Olbricht, Christoph J. ; Marcen, Roberto ; Sester, Urban ; Kunzendorf, Ulrich ; Dietl, Karl Heinz ; Rigotti, Paolo ; Ronco, Claudio ; Hörsch, Silke ; Banas, Bernhard ; Mühlbacher, Ferdinand ; Arias, Manuel. / Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation : 7-Year observational results. In: Transplant International. 2016 ; Vol. 29, No. 3. pp. 307-314.
@article{679c5569ed204f04a41976c50265cba0,
title = "Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation: 7-Year observational results",
abstract = "The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1{\%} in the tacrolimus arm and 59.9{\%} in the CsA-ME arm, graft survival rates amounted to 82.6{\%} and 80.6{\%}, and patient survival rates to 89.9{\%} and 88.1{\%}. Estimated combined endpoint-free survival rates were 60.2{\%} in the tacrolimus arm and 47.0{\%} in the CsA-ME arm (P =",
keywords = "acute rejection, adverse events, calcineurin inhibitor, investigator-initiated study, long-term follow-up",
author = "Kr{\"a}mer, {Bernhard K.} and Giuseppe Montagnino and Bernd Kr{\"u}ger and Raimund Margreiter and Olbricht, {Christoph J.} and Roberto Marcen and Urban Sester and Ulrich Kunzendorf and Dietl, {Karl Heinz} and Paolo Rigotti and Claudio Ronco and Silke H{\"o}rsch and Bernhard Banas and Ferdinand M{\"u}hlbacher and Manuel Arias",
year = "2016",
month = "3",
day = "1",
doi = "10.1111/tri.12716",
language = "English",
volume = "29",
pages = "307--314",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Efficacy and safety of tacrolimus compared with ciclosporin-A in renal transplantation

T2 - 7-Year observational results

AU - Krämer, Bernhard K.

AU - Montagnino, Giuseppe

AU - Krüger, Bernd

AU - Margreiter, Raimund

AU - Olbricht, Christoph J.

AU - Marcen, Roberto

AU - Sester, Urban

AU - Kunzendorf, Ulrich

AU - Dietl, Karl Heinz

AU - Rigotti, Paolo

AU - Ronco, Claudio

AU - Hörsch, Silke

AU - Banas, Bernhard

AU - Mühlbacher, Ferdinand

AU - Arias, Manuel

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1% in the tacrolimus arm and 59.9% in the CsA-ME arm, graft survival rates amounted to 82.6% and 80.6%, and patient survival rates to 89.9% and 88.1%. Estimated combined endpoint-free survival rates were 60.2% in the tacrolimus arm and 47.0% in the CsA-ME arm (P =

AB - The European Tacrolimus versus Ciclosporin-A Microemulsion (CsA-ME) Renal Transplantation Study demonstrated that tacrolimus decreased acute rejection rates at 6 months. Primary endpoints of this investigator-initiated, observational 7-year follow-up study were acute rejection rates, patient and graft survival rates, and a composite endpoint (BPAR, graft loss, and patient death). We analyzed data from the original intent-to-treat population (n = 557; 286 tacrolimus, 271 CsA-ME). A total of 237 tacrolimus and 208 CsA-ME patients provided data. At 7 years, Kaplan-Meier estimated rates of patients free from BPAR were 77.1% in the tacrolimus arm and 59.9% in the CsA-ME arm, graft survival rates amounted to 82.6% and 80.6%, and patient survival rates to 89.9% and 88.1%. Estimated combined endpoint-free survival rates were 60.2% in the tacrolimus arm and 47.0% in the CsA-ME arm (P =

KW - acute rejection

KW - adverse events

KW - calcineurin inhibitor

KW - investigator-initiated study

KW - long-term follow-up

UR - http://www.scopus.com/inward/record.url?scp=84958623991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958623991&partnerID=8YFLogxK

U2 - 10.1111/tri.12716

DO - 10.1111/tri.12716

M3 - Article

VL - 29

SP - 307

EP - 314

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 3

ER -